ALSO NOTED: FDA meets with NeoPharm; Corcept's CFO steps down; and much more...

> The FDA's Office of Oncology has met with NeoPharm over the fate of Cintredekin Besudotox, telling company officials that another late-stage trial would be needed before any approval could be expected. NeoPharm announced last December that the drug had failed in Phase III, sending its stock price into a nose dive. The company announced earlier this week that its CEO was out the door and a replacement was taking his place. In a statement, NeoPharm said it is "disappointed with the Office of Oncology's position, which, if implemented, would significantly delay the introduction of this therapy to GBM patients. The company will consider its options to determine the best path forward and will communicate its plans when they are completed and approved by the board of directors." Release

> Switzerland has rejected Roche's Tarceva as a therapy for pancreatic cancer. This is the second time Swiss officials have rejected Tarceva, citing safety and efficacy results. Report

> Hollis-Eden has filed an IND for HE3286, a treatment of metabolic disorders, which include diabetes, obesity and dyslipidemia. A separate IND for autoimmune disorders is also being planned. Report

> Chutes & Ladders: The day after announcing a severe cash crunch, Corcept Therapeutics announced that CFO Fred Kurland had left to take a similar position at another company. Release

> Korea's Dong-A PharmTech announced positive results from a Phase IIb trial of udenafil for erectile dysfunction. Report

> Alpharma has inked a licensing deal with Tris Pharma that will give it access to Tris' LiquiXR technology, a drug delivery platform for sustained release products in liquid form. Release

> Cytori Therapeutics has entered into a deal with Green Hospital Supply, which will purchase 1.0 million shares of Cytori common stock at $6.00 per share. Report

And Finally… Samsung Electronics is developing nanobots that can circulate through the human body, detecting disease and delivering therapeutics. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.